Answers are grounded in this paper and cite their sources.
In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (Funded by Insmed; WILLOW ClinicalTrials.gov number, NCT03218917.).
No takes yet. Share an insight, caveat, or question.
Chalmers et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: